NCT01608165

Brief Summary

The number of people diagnosed with kidney cancer has doubled over the past 20 years, making it the eight most common cancer in the UK. Most tumours are less than 4cm in size, but over 80% of these are malignant (cancerous) and if left untreated, will slowly grow and spread. Current standard treatment for these small kidney cancers is to remove the diseased part of the kidney in an operation called a partial nephrectomy, but this can be quite a difficult operation. Because of the small tumour size and difficulties with the operation, other treatments have been developed to destroy the tumours. These treatments include radiofrequency ablation, which means that the tumour is destroyed by heat, and cryoablation, which means that the tumour is frozen and destroyed. Although removing the part of the diseased kidney in an operation is the tried and tested way to treat the kidney cancer, it does have risks and complications, such as bleeding. The other two treatments are less intrusive to the patient, and are less complicated as they do not require such a large operation as having part of the kidney removed, but it is not known if they are as good at destroying all of the tumour, and whether or not patients who have their tumour destroyed with these new methods require further treatment in future. In this study, the investigators are trying to determine if a large-scale study comparing these treatments is possible which is why this is called a feasibility study. The investigators are also looking at whether patients would be willing to be randomly assigned to a treatment group. The results of this study will then be compared to see how effective each of the treatments were and whether the number of patients who were happy to be randomly assigned to a treatment could be used to determine the number of patients required in a large-scale trial.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2012

Typical duration for not_applicable

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 25, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 30, 2012

Completed
2 days until next milestone

Study Start

First participant enrolled

June 1, 2012

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

December 7, 2015

Status Verified

December 1, 2015

Enrollment Period

2.3 years

First QC Date

May 25, 2012

Last Update Submit

December 4, 2015

Conditions

Keywords

Small renal cancer mass

Outcome Measures

Primary Outcomes (1)

  • The proportion of patients who agree to trial registration and accept randomisation

    To estimate the proportion of patients with renal masses \< 4cm who agree to trial registration and accept randomisation to either partial nephrectomy or one of the ablative techniques

    18 months

Secondary Outcomes (8)

  • SF-36 quality of life questionnaire

    at 7 days of randomisation and at 3 to 6 months follow up

  • EQ-5D quality of life questionnaire

    Within 7 days of randomisation, and at 3 and 6 months follow up

  • FACT-G quality of life questionnaire

    Within 7 days, and 3 and 6 month follow-up

  • Hospital anxiety and depression questionnaire

    Within 7 days, and 3 and 6 month follow up

  • Differences in results in pre and post treatment CT scans

    at 1, 3 and 6 months after surgery

  • +3 more secondary outcomes

Study Arms (3)

Partial nephrectomy

OTHER

Patients randomised to this arm will undergo a partial nephrectomy

Procedure: Surgical treatment for renal mass

Radiofrequency ablation

OTHER

Patients randomised to this arm will undergo radiofrequency ablation

Procedure: Percutaneous Radiofrequency ablation

cryoablation

OTHER

Patients randomised to this arm will undergo cryoablation

Procedure: Laparascopic or percutaneous cryoablation

Interventions

Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass

Partial nephrectomy

Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass

Radiofrequency ablation

Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass

cryoablation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age greater than or equal to 18 years
  • ASA physical status classification system of 1 or 2
  • Radiological confirmation of (\>20 Hounsfield Unit) enhancing renal mass (\< 4cm) or biopsy proven renal cancer
  • CT abdomen/chest/pelvis with no enlarged nodes or distant metastases
  • Patient has provided written informed consent for participation in the study prior to any study specific procedures

You may not qualify if:

  • Coagulopathy
  • Concomitant disease that would render the patient unsuitable for the study
  • Presence of urosepsis
  • Cancer which is completely buried in the kidney
  • More than one small renal cancer mass
  • Previous participation in this study
  • Inability to give informed consent; carer/proxy assent will not be allowed in this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

South Mead Hospital

Bristol, United Kingdom

Location

Gartnavel Hospital

Glasgow, United Kingdom

Location

Guys and St Thomas Hospital

London, United Kingdom

Location

St George's Hospital

London, United Kingdom

Location

Freeman Hospital

Newcastle upon Tyne, United Kingdom

Location

MeSH Terms

Conditions

Kidney Neoplasms

Interventions

Surgical Procedures, OperativeCatheter Ablation

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Radiofrequency AblationRadiofrequency TherapyTherapeuticsAblation Techniques

Study Officials

  • Naeem Soomro

    Newcastle upon Tyne Hospitals NHS Foundation Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2012

First Posted

May 30, 2012

Study Start

June 1, 2012

Primary Completion

October 1, 2014

Study Completion

January 1, 2015

Last Updated

December 7, 2015

Record last verified: 2015-12

Locations